Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Cervical Dystonia Clinical Trial

Official title:

Prospective, Open-label Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05157100
• Other study ID #: 1002
• Status: Completed
• Phase: Phase 4
• Start date: October 19, 2021
• Est. completion date: September 15, 2023

Study information

• Verified date: October 2023
• Source: The Orthopedic Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.

Description:

The study will be an open-label, prospective study. Patients with a diagnosis of cervical dystonia will undergo 4 weeks of baseline evaluation, followed by a 12-week treatment period. Subjects will be evaluated in-clinic every 4 weeks. Standardized assessments will be performed at these visits. Data will also be collected from wearable IMUs (inertial measurement units) and analyzed for improvements in involuntary, repetitive movements and postures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 15, 2023
• Est. primary completion date: September 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male or female patients between 18 and 85 years of age (inclusive)

• A clinical diagnosis of cervical dystonia (ie, spasmodic torticollis) by investigator for at least six months

• Moderate to severe head tremor and/or dystonic posturing as judged by the investigator

• Stable Botulinum Toxin (Botox, Dysport, Xeomin, or Myobloc) therapy dosage for at least 3 months prior to baseline visit

Exclusion Criteria

• Tardive dyskinesia

• Predominant anterocollis

• Concomitant use of strong CYP3A4 inhibitors (i.e. itraconazole, ketoconazole, clarithromycin), digoxin, strong CYP2D6 inhibitors (i.e. paroxetine, fluoxetine, quinidine), monoamine oxidase inhibitors (i.e. isocarboxazid, phenelzine, selegiline)

• Myotomy or denervation surgery in the affected muscles (eg, peripheral denervation and/or spinal cord stimulation)

• Diagnosis of Myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial

• Moderate to severe hepatic impartment as determined by a Child-Hugh Score =7

• Marked limitation on passive range of motion that suggests contractures or other structural abnormality, eg, cervical contractures or cervical spine syndrome

• Any conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study

• Participation in another interventional study during participation in this study

• Pregnant or lactating females, or females of child-bearing potential not willing to use an acceptable method of contraception

• History of hypersensitivity to valbenazine or any components of INGREZZA.

• Is suicidal at screening as defined by below:

1. According to the C-SSRS, he or she must not be actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline) (including, an answer of "yes" to C-SSRS questions 4 or 5 [current or over the last 6 months]) and must not have attempted suicide in the 1 year prior to Visit 1 (Screening); OR

2. The subject is actively suicidal in the Investigator's judgment

Related Conditions & MeSH terms

• Cervical Dystonia
• Dystonia
• Dystonic Disorders
• Torticollis

Intervention

Drug:
• Ingrezza Pill
Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.

Locations

Country	Name	City	State
United States	The Orthopedic foundation	New Albany	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Orthopedic Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in incidence of pain/spasm	Change in incidence rate of pain/spasm as measured by frequency and intensity in subjects prior to and during use of valbenazine as measured by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and Inertial measurement unit (IMU). TWSTRS is a composite scale used to measure three aspects of CD: severity, disability, and pain. TWSTRS total score falls within the range of 0 to 85, where a higher score indicates a more severe condition.	16 weeks